Takeda Celebrates 110 Years of Innovation at Osaka Manufacturing Site

2025年11月11日

110 Years of Patient-Driven Innovation

Takeda’s Osaka Manufacturing Site exemplifies next-generation pharmaceutical production, integrating Artificial Intelligence, robotics, and digital technologies to drive quality and efficiency. Innovations such as predictive maintenance, AI-powered inspections, and automated aseptic filling are transforming medicine manufacturing.

Osaka’s pioneering production models include AI-powered motion analysis in aseptic operations, 3D printing for rapid shop floor innovation, drone-assisted safety inspections, and digitalized quality labs.

“The Osaka Manufacturing Site exemplifies our belief that technology and dedicated people working together can transform what is possible in medicine. As we look ahead, Takeda remains committed to investing in innovation and in our people, in Japan and beyond, for the benefit for our patients.” said Thomas Wozniewski, Global Manufacturing and Supply Officer, Takeda.

Strategic Investments in Japan and Global Health

The Osaka celebration highlighted Takeda’s broader commitment to innovation and investment in Japan, including recent capital projects such as a new production line in Osaka for future demand for a key oncology product, and a state-of-the-art facility in Hikari for a key global gastrointestinal product.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com/jp.

Contact

Kumi Iiyama
[email protected]
080-5789-7742

Important Notes

For the purposes of this notice, "press release" means this document and any oral presentation, question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") in connection with this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular company. Product names mentioned in this press release are trademarks or registered trademarks of Takeda or their respective owners.

Forward-Looking Statements

This press release and materials distributed in connection with this press release contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Forward-looking statements often include, but are not limited to, words such as "targets," "plans," "believes," "hopes," "continues," "expects," "aims," "intends," "ensures," "will," "may," "should," "would," "could," "anticipates," "estimates," "projects" or similar expressions or the negative of these terms. These forward-looking statements are based on assumptions about many important factors, and actual results may differ materially from the future results expressed or implied by such forward-looking statements. the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States, and the state of international trade relations; the emergence and development of competitive products; changes to applicable laws and regulations, including global healthcare reform, including taxes, tariffs and other trade-related regulations; the difficulties inherent in new product development, including uncertainties of clinical success and regulatory decisions and the timing thereof; uncertainty of the commercial success of new and existing products; difficulties or delays in manufacturing; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, such as the novel coronavirus pandemic, on Takeda, its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of Takeda's business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's business and the timing of any such asset divestitures; https://www.takeda.com/jp/investors/sec-filings-and-security-reports/ ) or www.sec.gov. These factors include Takeda's most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.uk/securities/exchange/regulatory/compliance, as well as other factors identified in Takeda's other reports. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or information of Takeda in this press release may not be indicative of, and are not a forecast, prediction, guarantee or projection of Takeda's future results.

Osaka, Japan – November 11, 2025 – Takeda commemorated today the 110th anniversary of its Osaka Manufacturing Site, marking more than a century of pioneering contributions to global health and a dedication to pharmaceutical innovation for patients in Japan and around the world. Founded in 1915 as Takeda’s first owned manufacturing facility in Japan, the Osaka site has evolved into a hub of advanced pharmaceutical production, delivering world-class medicines while consistently demonstrating technological progress. ## 110 Years of Patient-Driven Innovation Takeda’s Osaka Manufacturing Site exemplifies next-generation pharmaceutical production, integrating Artificial Intelligence, robotics, and digital technologies to drive quality and efficiency. Innovations such as predictive maintenance, AI-powered inspections, and automated aseptic filling are transforming medicine manufacturing. Osaka’s pioneering production models include AI-powered motion analysis in aseptic operations, 3D printing for rapid shop floor innovation, drone-assisted safety inspections, and digitalized quality labs. “The Osaka Manufacturing Site exemplifies our belief that technology and dedicated people working together can transform what is possible in medicine. As we look ahead, Takeda remains committed to investing in innovation and in our people, in Japan and beyond, for the benefit for our patients.” said Thomas Wozniewski, Global Manufacturing and Supply Officer, Takeda. ## Strategic Investments in Japan and Global Health The Osaka celebration highlighted Takeda’s broader commitment to innovation and investment in Japan, including recent capital projects such as a new production line in Osaka for future demand for a key oncology product, and a state-of-the-art facility in Hikari for a key global gastrointestinal product. ## About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com/jp. ## Contact Kumi Iiyama [[email protected]](mailto:[email protected]) 080-5789-7742 ## Important Notes Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com/jp. For the purposes of this notice, "press release" means this document and any oral presentation, question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") in connection with this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular company. Product names mentioned in this press release are trademarks or registered trademarks of Takeda or their respective owners. ## Forward-Looking Statements This press release and materials distributed in connection with this press release contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Forward-looking statements often include, but are not limited to, words such as "targets," "plans," "believes," "hopes," "continues," "expects," "aims," "intends," "ensures," "will," "may," "should," "would," "could," "anticipates," "estimates," "projects" or similar expressions or the negative of these terms. These forward-looking statements are based on assumptions about many important factors, and actual results may differ materially from the future results expressed or implied by such forward-looking statements. the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States, and the state of international trade relations; the emergence and development of competitive products; changes to applicable laws and regulations, including global healthcare reform, including taxes, tariffs and other trade-related regulations; the difficulties inherent in new product development, including uncertainties of clinical success and regulatory decisions and the timing thereof; uncertainty of the commercial success of new and existing products; difficulties or delays in manufacturing; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, such as the novel coronavirus pandemic, on Takeda, its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of Takeda's business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's business and the timing of any such asset divestitures; https://www.takeda.com/jp/investors/sec-filings-and-security-reports/ ) or [www.sec.gov](https://www.sec.gov/). These factors include Takeda's most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.uk/securities/exchange/regulatory/compliance, as well as other factors identified in Takeda's other reports. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or information of Takeda in this press release may not be indicative of, and are not a forecast, prediction, guarantee or projection of Takeda's future results.

Takeda Celebrates 110 Years of Innovation at Osaka Manufacturing Site | Takeda Pharmaceuticals